Article
Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
Human mutation - 1 Oct 2006
Zheng Li, Wang Fengwei, Qian Chiping, Neumann Roxann M, Cheville John C, Tindall Donald J, Liu Wanguo
Abstract excerpt
Genetic defects in CHEK2 and TP53 have been implicated in prostate cancer development. However, the interaction of these two genes in prostate cancer tumorigenesis has not been investigated. We previously described 11 CHEK2 mutations in a group of 84 primary prostate tumors. In this report, we screened the same group of tumors for TP53 mutations and revealed nine somatic and two germline mutations. One germline...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.